Merck's Keytruda hits overall survival goal in early lung cancer as FDA decision nears
Fierce Pharma
OCTOBER 10, 2023
What doctors described as a “messy” treatment landscape in early-stage non-small cell lung cancer (NSCLC) could get clearer thanks to a first-in-class overall survival win from Merck & Co.’s s Keytruda.
318 
Let's personalize your content